New and future therapies for lupus nephritis.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22301564.
- Also identified by DOI 10.3949/ccjm.78gr.11004.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Based on data from randomized controlled trials over the past decade, oral mycophenolate (CellCept) now rivals intravenous cyclophosphamide (Cytoxan) as a first-line therapy for lupus nephritis, offering similar efficacy but less toxicity. The roles of rituximab (Rituxan) and new immunomodulatory agents are being explored. Creativity in treating lupus nephritis is needed; one regimen does not fit all.
Medical subject headings
- Immunosuppressive Agents
- Lupus Nephritis